CAS 208993-54-8: Fiduxosin
Description:Fiduxosin is a chemical compound classified as a selective antagonist of the alpha-1 adrenergic receptor, primarily used in the treatment of benign prostatic hyperplasia (BPH). It functions by relaxing the smooth muscles in the prostate and bladder neck, thereby improving urinary flow and reducing symptoms associated with BPH. The molecular structure of fiduxosin includes a piperidine ring, which contributes to its pharmacological activity. It exhibits a favorable pharmacokinetic profile, with good oral bioavailability and a moderate half-life, allowing for once-daily dosing. Additionally, fiduxosin has been studied for its potential effects on cardiovascular parameters, although it is primarily focused on urological applications. As with many medications, potential side effects may include dizziness, fatigue, and orthostatic hypotension, particularly upon initiation of therapy. Overall, fiduxosin represents a targeted approach in managing urinary symptoms related to prostate enlargement, with ongoing research into its broader therapeutic implications.
Formula:C30H29N5O4S
InChI:InChI=1S/C30H29N5O4S/c1-38-22-10-7-11-23-24(22)20-16-34(15-19(20)17-39-23)12-5-6-13-35-29(36)27-25(33-30(35)37)26-28(40-27)31-14-21(32-26)18-8-3-2-4-9-18/h2-4,7-11,14,19-20H,5-6,12-13,15-17H2,1H3,(H,33,37)/t19-,20-/m1/s1
InChI key:InChIKey=WDTAYDBPNYFWDR-WOJBJXKFSA-N
SMILES:O=C1NC=2C=3N=C(C=NC3SC2C(=O)N1CCCCN4CC5C=6C(OC)=CC=CC6OCC5C4)C7=CC=CC=C7
- Synonyms:
- 8-Phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
- 8-Phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl]butyl]pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione
- Fiduxosin
- Pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, 8-phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl]butyl]-
- pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione, 8-phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl]butyl]-
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
![]() | Fiduxosin REF: TR-F335540CAS: 208993-54-8 | - - - | 34,767.00 € | Tue 06 May 25 |
![]() | Fiduxosin-d6 REF: TR-F335542CAS: 208993-54-8 | - - - | 37,343.00 € | Tue 06 May 25 |
![]() | Fiduxosin REF: 3D-IIA99354CAS: 208993-54-8 | Min. 95% | 1,637.00 € | Wed 07 May 25 |
![]() | Fiduxosin REF: TM-T11286CAS: 208993-54-8 | 99.73% | 665.00 €~1,710.00 € | Wed 28 May 25 |

Fiduxosin
Controlled ProductRef: TR-F335540
25mg | 34,767.00 € |

Fiduxosin-d6
Controlled ProductRef: TR-F335542
25mg | 37,343.00 € |

Fiduxosin
Ref: 3D-IIA99354
1mg | 1,637.00 € |

Fiduxosin
Ref: TM-T11286
1mg | 665.00 € | ||
5mg | 1,710.00 € |